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a b s t r a c t
Ethnopharmacological relevance: The stem barks of Lafoensia pacari have been traditionally used not only
by South Amerindians but also by Brazilian and Paraguayan populations for treating a variety of
unhealthy conditions to which their biological potential has been scientiﬁcally documented in several
reports over the last decade. Although its anticancer usage is also popular, no scientiﬁc support for such
activity has been found.
Aim: To provide scientiﬁc evidence for the anticancer popularity of Lafoensia pacari.
Materials and methods: Extracts prepared according to the popular use along with a methanol extract
and its four fractions were produced from Lafoensia pacari stem barks. The chromatogram proﬁle of each
one was obtained by HPLC. Several tumor cell lines were exposed to these solutions in in vitro assays and
the effects evaluated by morphological, growth, and cell cycle status changes.
Results: High toxicity determined by the lactate dehydrogenase levels with a signiﬁcant drop in the cell
proliferation index were found for all cell lines included in this study after exposition to Lafoensia pacari
extract and fractions. The morphological features along with the expression of annexin V have strongly
suggested apoptosis induction, which has been conﬁrmed by G0/G1 cell cycle arrest.
Conclusions: The data have clearly shown that exposition of human tumor cell lines to Lafoensia pacari
stem barks extract leads to apoptosis induction due to cell cycle arrest in G0/G1 phases, supporting its
anticancer use.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Lafoensia pacari A. St.-Hil., Lythraceae, is a decidual tree that
grows mostly in the Pantanal and Cerrado biomas of Brazil. Known
as “dedaleira” or “mangava-brava”, its stem barks have been
traditionally used as a tonic and for treating inﬂammation condi-
tions particularly related to gastric ulcers, wounds or fevers
(Tamashiro Filho et al., 2012).
Named “precious wood” by the Tupi-Guarani Amerindians and
“morosyvó” by Eastern Paraguayans, Lafoensia pacari barks have also
been taken to treat several types of cancer (de Melo et al., 2011).
Interestingly, the folk remedy has at least two ways of preparation:
bark aqueous decoction (DEC) and cold-water long-standing
maceration (MAC) (Solon et al., 2000).
The amount of data published over the last decade or so
concerning to the biological potential of Lafoensia pacari has been
considerably extensive in which its anti-inﬂammatory (Guimaraes
et al., 2010; Rogerio et al., 2008), anti-allergic (Rogerio et al., 2010),
analgesic (Nascimento et al., 2011), anti-edematous (Rogerio et al.,
2006), microbicidal (de Lima et al., 2006; Porﬁrio et al., 2009; Silva
et al., 2010), antiviral (Müller et al., 2007), antioxidant (Galano
et al., 2014; Solon et al., 2000), sedating, and antidepressant-like
effects (de Matos et al., 2008; Galdino et al., 2009) have been
scientiﬁcally documented, and some of them even elucidated at a
mechanistical level, corroborating its many traditional uses.
Some of these and other studies have also provided information
that places the ellagic acid (EA), the phenolic phytochemical marker of
the species, as the activities´ major protagonist including the anti-
tumor effects (Berni et al., 2012; Narayanan et al., 1999; Nascimento
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et al., 2011; Pari and Sivasankari, 2008; Rogerio et al., 2008, 2006;
Solon et al., 2000; Umesalma and Sudhandiran, 2010, 2011).
Although it has been recently reported that an ethanolic extract
prepared from its stem barks is not mutagenic according to the
in vitro Ames assay, and genotoxicity could be achieved only at
high doses using the in vivo mouse bone marrow micronucleus
test (Lima et al., 2013), studies concerning to Lafoensia pacari
cancer-related uses are lacking. As such and aiming to clarify and
support the anticancer popular usage of Lafoensia pacari, we have
conducted an in vitro study using several tumor cell lines.
The results herein presented have clearly shown, for the ﬁrst
time, that exposition of human leukemic cell lines as well as others
representatives of cervical, colon, and neuroblastoma human
cancers to Lafoensia pacari stem barks extract leads to changes
characteristics of apoptosis induction, including morphological
aspects and alteration of the cell cycle status.
2. Material and methods
2.1. Reagents and chemicals
Unless otherwise speciﬁed, all solid and liquid chemicals used
in this work were purchased from Sigma (São Paulo, BR) or Merck
(São Paulo, BR) representatives.
2.2. Plant material, extracts and fractions preparation
Stem barks of Lafoensia pacari A. St.-Hil. were collected in the
surroundings areas of Maracaju (21145037.4″S,55121081.9″WO),
Mato Grosso do Sul state, Brazil, in May 2011, under the govern-
mental Normative Instruction No. 154/2007/SISBio regulation,
receiving the 29123-1 authorization. They were identiﬁed by the
Botanist Gerdt Hatschbach and a voucher specimen under the
Protocol MBM11065 has been deposited at the Per Karl Dusén
Collection of the Museu Botânico de Curitiba, Paraná State, Brazil.
The plant material was air dried at room temperature for ﬁve days
followed by three days at 60 1C. Dried and fragmented barks (10 g)
were macerated in double distilled water for 24 h in a domestic
refrigerator (4–8 1C) or boiled for 10 min to prepare the cold-water
long standing macerate (MAC) and the aqueous decocted (DEC)
extracts, respectively. Powdered bark material (300 g/0.425 mm
mesh) was also exhaustively macerated in MeOH for 72 h in the
dark, at room temperature, ﬁltered, and evaporated under pres-
sure to dryness at 60 1C (26.5% w/w yield). The methanolic extract
(ExtMeOH—60 g) was kept in cold water (900 mL) for 8 h under
agitation, and a precipitate gave rise to the hydrophobic fraction
(F1; 5.64% w/w yield). The dissolved material was partitioned
(3100 mL) with ethyl acetate (F2; 0.39% w/w yield), n-butanol
(F3; 3.78% w/w yield), and water (F4; 7.96% w/w yield). Each
extract and fractions were lyophilized and kept at minus 25 1C. For
the biological experiments, extracts and fractions were prepared
at 4% (w/v) in DMSO and further diluted to 1% directly into RPMI
1640 (Himedia Laboratories; Mumbal, India) or IMDM (Gibco;
Paisley, UK) media supplemented with 10% heat-inactivated fetal
calf serum (FCS—Cultilab; Campinas, São Paulo, BR). After sterilized
through a 0.22 mm pore size ﬁlter, 1 mL aliquots were stored at
minus 25 1C. Final concentrations varying from 0.1 to 1000 μg/mL
were obtained by thawing and diluting the 1% stock solution in the
appropriate culture medium just before the experiments.
2.3. HPLC-PAD analyses
The analysis was performed by a Varian ProStar Gradient high
performance liquid chromatography coupled with photodiode
array detector (HPLC-PAD) consisting of a Solvent Delivery Module
(Mod. 230), an Auto Sampler (Mod. 410) injector, and a Photodiode
Array Detector (Mod. 335) coupled to the chromatograph. A 5 μm
Kromasil C-18, 4.6250 mm analytical column maintained at room
temperature was used. Samples of the DEC, MAC, and ExtMeOH
extracts as well as of the four fractions and ellagic acid (12.48 mg/mL),
were dissolved in MeOH, ﬁltered with 0.45 μm nylon ﬁlters and
injected in the HPLC-PAD instrument using a solvent system con-
sisting of (A) acidulated water puriﬁed by a Milli-Q system (Milipore
Milford, MA), with 0.1% phosphoric acid, and (B) methanol. The
solvents were run at a ﬂow rate of 1.0 mL/min using the following
linear gradient: 5% B to 65% B for 40 min, 65% B to 95% B for 5 min,
5% B for 5 min. Detection was monitored at 270 nm to compare
chromatographic proﬁles. After that, triplicate samples of the
ExtMeOH (1 mg/mL) and of the hydrophobic (F1; 1 mg/mL), ethyl
acetate (F2; 0.08 mg/mL), n-butanol (F3; 0.4 mg/mL), and aqueous
(F4; 1 mg/mL) fractions were prepared, ﬁltered with 0.45 μm nylon
ﬁlters, injected using de same HPLC-PAD conditions, and detection
for ellagic acid was monitored at 270 nm and expressed in μg/mg
(or μM). Chromatographic peak has been identiﬁed by comparing the
retention time with standard recorded under the same conditions.
A calibration curve was obtained with a commercial ellagic acid
standard after dilution in methanol (1.04 to 12.48 μg/mL). The
correlation coefﬁcient obtained for ellagic acid was r2¼0.999.
2.4. Cell lines and maintenance
The U-937, Jurkat, and Daudi leukemic cell lines were pur-
chased from Rio de Janeiro Cell Bank, Universidade Federal do Rio
de Janeiro (RJBC; Rio de Janeiro, BR). HeLa and HRT-18 cell lines
were kindly provided by Dr. K. S. Paludo (Departamento de
Biologia Estrutural, Molecular e Genética, Universidade Estadual
de Ponta Grossa, Ponta Grossa, Brazil); the SH-SY5Y cell line was
kindly provided by Dr. R. F. Bachinski (Centro de Ciências Médicas,
Universidade Federal Fluminense, Rio de Janeiro, Brazil). All cell
lines were kept at 37 1C in a 5% CO2 humidiﬁed atmosphere in
RPMI 1640 or IMDM full medium, consisting of 10% FCS, 2 mM
L-glutamine, 3 g/L sodium bicarbonate, 100 IU/mL G-penicillin,
and 50 mg/mL streptomycin sulphate. Twice a week, the cells were
split at 105 cells/mL ratio. For the experiments, all cell lines were
harvested at the exponential growth phase and checked for
viability using the Trypan Blue assay, in which the number of
viable cells always exceeded 90%.
2.5. Cell viability and toxicity
Toxic effects of the extract and fractions from 0.1 to 1000 mg/mL
and of all solutions used in this study on peripheral blood, bone
marrow cells, and cell lines were evaluated using the Trypan Blue
assay. Viability was taken as the percentage of cells not incorpor-
ating the stain7one standard deviation (1 SD), counted in a
hemocytometer after directly diluting the cell suspension with
0.4% Trypan Blue solution.
2.6. Proliferation assay
For each cell line, cell suspensions in full medium were
distributed into ﬂat-bottomed 24- or 96-well culture dishes
(TPP; Switzerland) and left for 24 h at 37 1C in a fully humidiﬁed,
5% CO2 incubator. Extract solution was then added to give ﬁnal
concentrations ranging from 0.1 to 1000 mg/mL in a 1000 or 200 mL
ﬁnal volume/well and further incubated for 6 h to ﬁve days. For
mouse bone marrow cells, a 100 mL containing 2104 MNC in full
IMDM mediumwere seeded per well and simultaneously added of
extract (0.1 to 1000 mg/mL) in a 200 mL ﬁnal volume/well for a
week. The number of cells recovered was evaluated in a hemo-
cytometer. Each experiment was performed in triplicates and the
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results were expressed as the mean cell number recovered71 SD
after incubation or as a proliferation index, of at least three
independent experiments.
2.7. Lactate dehydrogenase (LDH) assay
LDH assay was performed with U-937 cells treated with 10,
100, and 1000 mg/mL of extract for 24 h at 37 1C in a fully
humidiﬁed, 5% CO2 incubator by assessing the enzyme content
released into the media as a marker of dead cells and the enzyme
present in the cell lysates (LDHCL)) as a marker of remaining living
cells using the LDH Liquiform commercial kit (Labtest Diagnóstica
S.A., Curitiba, Brazil). After incubation, the culture supernatants
were separated by spinning down at 400 g/5 min and used to
measure the LDH released into the media (LDHSPN) while the cell
pellets were treated with lysing buffer (0.1 M Tris–HCl pH 7.2 sup-
plemented with 1% Nonidet P-40, 0.01% SDS, 100 μM PMSF, and
1 μg/mL aprotinin) giving rise to cell lysates. The absorbances
obtained at 340 nm in a Cobas Mira Classic instrument (Roche)
were used to obtain the % of ﬁnal LDH according to the following
equations: Free LDH (%)¼(LDHSPN100)/(LDHSPNþLDHCL);
100(Free LDH %)¼% Final LDH.
2.8. Human mononuclear cells and phytohemagglutinin-elicitation
assay
The protocol used for human peripheral blood collection has
been approved by the Health Sciences Ethical Committee of the
Federal University of Paraná, CEP/SD, No. 039.SI003/04-01, which
is in accordance with the Declaration of Helsinki. The isolation of
the mononuclear cells (MNC) as well as the phytohemagglutinin-
elicitation assay were both performed essentially as described
elsewhere (Nardin et al., 2010).
2.9. Morphological assessment
Whereas morphology was accessed, 5–8104 cells cytocentri-
fuged using a CytoproTM instrument (Wescor, Utah, USA) were
stained with May-Grunwald–Giemsa protocol. At least 200 cells
per assay were observed and differentiated for each experiment
under immersion oil light microscopy.
2.10. Annexin V and 7-AAD co-expression by ﬂow cytometry
After 24 h of subculture at 37 1C, U-937, HeLa, HRT-18, and
SH-SY5Y cell lines as well as human peripheral MNC (106 cells/mL)
were treated with extract (10–1000 mg/mL) for 6, 12 or 24 h. The
treated cells were then washed with cold D-PBS, stained simulta-
neously with Annexin V-FITC (BD Bioscience, San Jose, CA, USA)
and 7-AAD (BD Bioscience, San Jose, CA, USA), and analyzed by
ﬂow cytometry using an FACS Calibur instrument (Becton &
Dickinson, San Diego, California, USA) and the strategies described
elsewhere (de Lima et al., 2010) in which at least 105 events were
acquired in the gated populations. Data were analysed using the
WinMDI 2.8 software. The results were expressed as the mean
percentage of positive cells for each population from at least three
independent experiments.
2.11. Cell cycle analysis
U-937 cells (106) exposed to 100 and 1000 mg/mL of extract
for 24 h at 37 1C were washed with cold D-PBS and ﬁxed for
30 min with 1% paraformaldehyde. After washing with cold D-PBS,
the cells were stained directly with 20 mL of a solution containing
propidium iodide (PI; 2 mg/mL), 300 mL RNase (10 mg/mL) and
Triton X-100 (0.3%) for 15 min in the dark at room temperature
followed by DNA content analysis in a FACS Calibur instrument,
in which 105 events per assay were acquired in a linear scale.
Histograms based on PI-stained cells were plotted by the WinMDI
2.8 software program that provides the estimate of percentage of
cells with fractional DNA content (apoptotic cells: Ap) and cells in
G1, S, and G2/M phases of the cycle.
2.12. Colony-forming assays
The clonogenic potential of U-937, Daudi, and Jurkat cells was
assayed by counting colonies grown in the commercial viscous
medium MethoCult™ (StemCell Technologies Inc.; Vancouver, CA)
supplemented with Stem Cell Factor (50 ng/mL), GM-CSF (10 ng/mL),
IL-3 (10 ng/mL), and erythropoietin (3 IU/mL) recombinant human
cytokines. The cells were ﬁrst washed with PBS, suspended into
IMDM medium supplemented with 10% FCS, and the concentration
adjusted to a density of 2105 cells/mL. To 1 mL of MethoCult, 103
cells were added. The mixture was plated in three aliquots of 0.3 mL
each into 24-well plastic culture dishes (TPP, Switzerland). Lafoensia
pacari methanol extract (1–100 mg/mL) was added to the plating
medium just before the cells. The dishes were incubated at 37 1C in a
fully humidiﬁed atmosphere supplemented with 5% CO2 in air. After
7–10 days, the colonies were scored by direct observation under an
inverted microscope. Each independent experiment was performed
in triplicates and the results were expressed as the mean colony
number71 SD.
2.13. Data analysis
Where applicable, differences between groups were analyzed
using Student’s t-test and one-way analysis of variance followed
by the Tukey HSD α¼0.05 multiple comparison test (PRISM
software, Graph Pad, La Jolla, CA). P values o0.05 were considered
statistically signiﬁcant.
3. Results and discussion
3.1. Plant extracts, fractions, and HPLC proﬁles
According to the popular usage, we have initially prepared two
extracts: one involving bark decoction (DEC) and the other based
on cold-water long-standing maceration (MAC). In parallel, a
methanol extract (ExtMeOH) following classical extraction proce-
dures was also prepared. HPLC analyses of these three solutions
have shown peaks with similar retention time (Fig. 1). The
standard biomarker ellagic acid (EA) at 12.48 mg/mL (41.1 μM)
resolved a peak at retention time of 34.5 min, and was identiﬁed
in all, with 5.24 mg/mg (17.3 μM) in DEC, 9.89 mg/mg (32.6 μM) in
MAC, and 9.05 mg/mg (29.9 μM) in ExtMeOH.
Partition of the ExtMeOH with solvents within a broad polarity
range led to four fractions (F1: hydrophobic; F2: EtOAc; F3:
n-BuOH; F4: aqueous) whose HPLC proﬁles were quite interest-
ingly as they all resembled the one presented by the mother
solution. EA was also present in these fractions, differing only in
concentration (28.1 μM in F1; 45.7 μM in F3, and 3.14 μM in F4),
being the predominant compound of F2 (253.4 μM). These results
showed that temperatures, time exposure or solvent polarity have
not inﬂuenced the ending compounds present in the extract.
3.2. Comparative effects of extracts, fractions, and ellagic acid
on U-937 cells behavior
To observe the effects on cell growth, U-937 cells, a mono-
blastic human leukemic cell line, were exposed to all these
solutions in concentrations ranging from 0.1 to 1000 mg/mL
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for 24 h. As shown in Fig. 2A, no interference on cell proliferation
status up to 10 mg/mL was observed in these short-term tests.
However, when compared to control values, a concentration-
related toxicity was present at higher concentrations, with a
signiﬁcant drop in the cell proliferation index. No cells could be
recovered from cultures in which the ﬁnal concentration was
1000 mg/mL. These ﬁndings were corroborated by the signiﬁcant
cytotoxicity determined by the lactate dehydrogenase (LDH) levels
(Fig. 2B).
Interestingly, EA assayed under the same protocol within a
broad concentration range corresponding to its presence within
solutions (0.3 to 3300 μM) showed signiﬁcantly lesser effects on
these parameters, and no toxicity up to 330 μM was observed
(Fig. 2A and B).
3.3. Inﬂuence of Lafoensia pacari extract on U-937 cells’ physical
properties
Once U-937 cells showed highly intoxicated with the ExtMeOH
extract, and based on the concept that when cells go into a death
process, their mechanical properties, generally represented by size
and inner complexity, change and the cells are able to alter their
capture position in a ﬂow cytometer, with a decrease in the optical
detection of these parameters, we exposed them to 100 mg/mL of
this extract for 24 h and measured their size (FSC) and inner
complexity (SSC). The results conﬁrmed the previous observations,
with signiﬁcant toxic effects promoted by the ExtMeOH treatment
(Fig. 2C). In contrast, no changes in the FSC and SSC parameters
obtained by ﬂow cytometry were detected in EA treated cells.
In addition, among the fractions tested, F2, which presented
the highest amount of EA, showed a pattern of effects not as
signiﬁcant as did the ExtMeOH or the other fractions, suggesting
that EA, at least as it is, and using the experimental settings
included in this study, is not the sole or the main compound
responsible for the effects described for the crude extract. Because
several studies have described the anti-proliferative and
apoptotic-induced potential of EA that naturally occurs in plants,
fruits, and vegetables, through modulation of several subcellular
signaling pathways, and anti-oxidant defense mechanisms
(Edderkaoui et al., 2013; Losso et al., 2004; Mishra and Vinayak,
2014a, b; Narayanan et al., 1999; Vanella et al., 2013; Zhang et al.,
2014), these results are of particular relevance for the potential of
the Lafoensia pacari extract itself as an anti-cancer remedy, open-
ing the possibility that one or more compounds apart from EA in
the extract are responsible for such a strong activity.
3.4. Morphological and proliferation effects of ExtMeOH on human
leukemic cell lines
As the MAC and DEC traditional folk remedies along with the
fractions have all showed similar HPLC proﬁles of the ExtMeOH,
have also evoked similar effects elicited by the methanolic
preparation alone, and are technically reproducible, we decided
to use only this extract to further study the Lafoensia pacari effects
upon other two leukemic cell lines in similar short-term assays,
but expanding the exposition time from 6 to 48 h.
Thus, Daudi and Jurkat cells, both of lymphoid origin, were
subjected to the same treatment performed with U-937 cells. As
showed in Fig. 3D, just after 6 h of treatment, cell viability and
recovery were both signiﬁcantly affected, even at lower concen-
trations such as 1 mg/mL. Once again, no cells at 1000 mg/mL were
recovered. The distinct effects on each cell line after extract
exposure may be better visualized in the panels A, B, and C
of Fig. 3, in which dramatic changes on cell phenotype were
observed in cytospun preparations stained with May-Grunwald–
Giemsa. Typical features of apoptosis induction were found in
contrast with the original morphology maintained by the
untreated population (panels 1-A, B and C). Within this context,
the presence of cytoplasmic vacuoli, chromatin condensation,
nuclear fragmentation, and formation of apoptotic bodies were
evident in the treated populations. After 48 h, the variable number
of naturally occurring cytoplasmic vacuoli had almost disappeared,
giving space to a prominent and intensely blue, reactive-like
cytoplasms in which, when present, nuclei with a highly con-
densed chromatin were immersed (panels 3-A, B and C).
3.5. Effects of ExtMeOH on human leukemic cells´ clonogenic
potential
These leukemic cell lines are able to generate colonies in soft
systems when appropriately stimulated. In order to investigate
whether the inhibitory effect would affect their clonogenic
response, they were exposed to 1 and 10 mg/mL of ExtMeOH. It
resulted in a concentration-dependent inhibition of colony forma-
tion for all when compared to the respective untreated popula-
tions. For U-937 cells the number of colonies increased from
100.0719.9 (control) to 124.0712.2 at 1.0 mg/mL followed by a
signiﬁcant decrease to 72.377.5 at 10 mg/mL (Po0.01). For Daudi
cells, the values decreased from 103.071.0 (control) to 86.0721.8
and 80.776.5, respectively for the same dose range (Pr0.01).
Finally, for Jurkat cells, the colony number signiﬁcantly declined
Fig. 1. Representative HPLC chromatograms of Lafoensia pacari extracts, fractions,
and ellagic acid (EA). Bark decoction (DEC); cold-water long-standing maceration
(MAC); methanol extract (ExtMeOH) and its hydrophobic (F1), ethyl acetate (F2),
n-butanol (F3), and aqueous (F4) fractions.
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from 84.776.7 (control) to 71.379.1 and 26.3726.3 at 1 and
10 mg/mL (Po0.05), respectively. At a 100 mg/mL, complete abro-
gation of colony formation response was observed for all cell lines.
It is important to note that, although the number of colonies was
affected, their size and morphology were not different from the
control experiments.
3.6. Apoptosis evaluation by ﬂow cytometry
Apoptosis can be detected not only on the basis of cell
morphology but also by ﬂow cytometric analysis of heterogeneous
cell populations, in which cell viability is preserved, allowing the
simultaneous detection of intact cells, cells undergoing apoptosis,
and dead cells resulting from apoptotic and/or necrotic processes
in the same sample and at the same time. To conﬁrm whether the
effects observed for leukemic cells were compatible with apoptosis
induction, we labelled U-937 cells exposed to Lafoensia pacari
ExtMeOH for 6 to 24 h with annexin V and 7-AAD and analysed
them by ﬂow cytometry.
Annexin V is a Ca2þ dependent phospholipid-binding protein
with high afﬁnity for phosphatidylserine (PS) present in the inner
side of the plasma membrane. In the early stages of apoptosis
changes difﬁcult to recognize occur at the cell surface, including
the translocation of PS from the inner side of the plasma
membrane to the outer layer, by which it becomes exposed at
the external cell surface. This phenomenon is present not only
during apoptosis, but occurs also during necrosis. The difference
between these two forms of cell death is that during the initial
stages of apoptosis the cell membrane remains intact, while at the
moment that necrosis occurs, the cell membrane integrity is lost
and the cell becomes leaky, allowing the entrance of molecules as
large as 7-AAD, which can be used to mark necrotic cells.
Therefore, in a ﬂow cytometric dot plot chart, the way cells
bind to annexin V (x axis) and/or 7-AAD (y axis) can discriminate
viable, intact cells (double negative staining/lower left quadrant)
from apoptotic cells (annexin V positive cells/lower right quad-
rant) and necrotic cells (double positive staining/upper right
quadrant), corresponding to the different stages of the apoptotic
cascade in vitro.
Fig. 2. Effects of Lafoensia pacari on U-937 cells. Exponentially growing U-937 cells were exposed to the indicated concentrations of Lafoensia pacari methanol extract
(ExtMeOH) or its hydrophobic (F1), ActOEt (F2), n-BuOH (F3) or aqueous (F4) fractions, and to ellagic acid (EA) for 24 h. (A) Each line represents the mean proliferation
index7SD of recovered cells estimated in a hemocytometer in relation to the untreated group (CT). (B) Mean percentage7SD of LDH content measured in U-937 cell lysates,
both obtained from at least three independent experiments, each one performed in triplicates. (C) Alteration of size (FSC) and inner complexity (SSC) morphological aspects
of ExtMeOH- and EA-treated U-937 cells optically captured by ﬂow cytometry when compared to untreated cells (CT). nnPo0.01; nnnPo0.001.
Fig. 3. Lafoensia pacari methanol extract effects on leukemic cell lines. Characteristic phenotypes of U-937 (A), Daudi (B), and Jurkat cells (C) stained with May-Grünwald–
Giemsa before (1) and after 6 (2) and 48 h (3) exposition to 1000 μg/mL of Lafoensia pacari methanol extract. Cell proliferation and viability of these cell lines (D) after 48 h
exposition to the indicated concentrations of extract. The vertical bars indicate the mean number7SD of the surviving fraction of leukemic cells counted in a
hemocytometer, and the lines indicate the mean percentage7SD of cell viability determined by the Trypan Blue exclusion assay in relation to the untreated population (CT)
from at least three independent experiments. nPo0.05, nnPo0.01, nnnPo0.001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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Using this strategy, the majority (495%) of the untreated intact
U-937 population (CT) was composed of healthy, viable cells at 0 h,
showing annexin V and 7-AAD double negative staining (Fig. 4A).
After 6 h and over, ExtMeOH treatment resulted in the appearance
of two distinct populations: one presenting annexin V single
positive expression, which was assigned for early apoptotic cells
(eAp), and other showing annexin V and 7-AAD double positive
staining (Fig. 4A/upper right quadrant), that we have referred as
late apoptotic cells (lAp). In Fig. 4B, it is possible to visualize that
these populations were also accompanied by a progressive and
signiﬁcant increase of a necrotic cell population (N).
Probably, the double positive labeled U-937 population was
composed of cells with the two distinct morphologies observed
in Fig. 3A.2 and A.3: one containing small, irregularly-shaped cells
with condensed and fragmented nuclei, consistent with cells in
the late stage of apoptosis, and one containing larger cells with
unfragmented nuclei that probably stained with 7-AAD, and were
suggestive of cells undergoing necrosis.
3.7. Effects of ExtMeOH on U-937 cell cycle
The results of the kinetics of apoptotic death of U-937 cells were
also compatible with the cell cycle analysis of these populations, in
which the cells were prepared to assess their relative DNA content
in different phases of the cell cycle by ﬂow cytometry (Fig. 5A).
In this assay the concentration-related increasing of the U-937
apoptotic population could be easily observed (Fig. 5B), varying
from 17.7072.34% in the control population (CT) to 33.3271.99%
at a 100 μg/mL, and 48.1575.15% at a 1000 μg/mL. Interestingly,
the signiﬁcant accumulation of cells in G0/G1 (36.0273.72%,
34.6970.52%, and 34.6474.74% for untreated cells, cells treated
with 100 and 1000 μg/mL, respectively) with the concomitant
decrease of cells in S phase (from 41.8574.35% to 34.7377.22
and 24.8173.88% respectively for control cells, cells treated with
100 and 1000 μg/mL) provide evidence that the observed apopto-
tic cell death induced by Lafoensia pacari ExtMeOH may be partly
due to cell cycle arrest in G0/G1 phase.
3.8. Effects of ExtMeOH on human cancer cell lines
Signiﬁcant results of apoptosis induction were also demon-
strated by HRT-18, SH-SY5Y, and HeLa human cell lines when
exposed to Lafoensia pacari ExtMeOH extract followed by annexin
V and 7-AAD treatment (Fig. 6A), broadening the anti-proliferative
effects of the plant. Worthy of note is that the apoptosis-induction
effects on these cell lines were observed at lower concentrations,
and only a few cells were observed in the late apoptosis gate (lAp)
for HeLa cells, suggesting a more prolonged retention on G1/G0
phase for these cells.
Fig. 4. Effects of Lafoensia pacari extract on U-937 cells. (A) Exponentially growing U-937 cells exposed to 1000 μg/mL of Lafoensia pacari stem barks extract for 6 to 24 h
were labelled with annexin-V and 7-AAD and subject to ﬂow cytometric analyses to identify subpopulations undergoing early (lower right quadrant/eAp), late (upper right
quadrant/ lAp) apoptosis or necrosis (upper left quadrant/N). Each bar represents the mean percentage71 SD of cells detected in each quadrant. nnnPo0.001 compared to
untreated (CT) population.
Fig. 5. Effects of Lafoensia pacari extract on U-937 cell cycle phases. Exponential growing U-937 cells were exposed to the indicated concentrations of Lafoensia pacari extract
for 24 h and analysed for cell cycle status by ﬂow cytometry. (A) The histograms are representative of one of at least three similar experiments of the dose-related DNA
content detected in each cell cycling phase. (B) Each bar represents the mean percentage71 SD of cells detected in each phase. Signiﬁcant differences were compared
between control (CT) and treated cells (nnPo0.01; nnnPo0.001).
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3.9. Effects of ExtMeOH on human peripheral mononuclear cells
Because cancer cells have different proliferative proﬁle when
compared to normal cells, we have used peripheral mononuclear
cells (MNC) from healthy donors, in which the majority are
lymphocytes that are not cycling under normal circumstances, to
test whether the apoptotic effects of Lafoensia pacari ExtMeOH on
tumor cells would also affect normal cells.
Exposition to 10 and 100 mg/mL of Lafoensia pacari ExtMeOH
for 24 h also triggered a concentration-related apoptosis in these
cells (Fig. 6B). However, this phenomenon was observed mainly
when MNC were previously stimulated to proliferate with phyto-
hemagglutinin (PHA-MNC), in which the number of late apoptotic
cells were signiﬁcantly higher than those observed for the unsti-
mulated population (Fig. 6C), suggesting that the effect of inducing
apoptosis rests on cells that are cycling and/or under intense
metabolic activity.
4. Conclusion
Mainly as an infusion or a decoct, many plants have been
traditionally used for the treatment of several diseases and have
gained recognition as biological response modiﬁers. A relevant
concern is the detection of effects present in these preparations
that may interfere with cell division. In this context, plants have
been a source of clinically relevant anticancer compounds and
nowadays a variety of natural products and derivatives belong to
the repertoire of cancer chemotherapeutic agents.
Because preparations of Lafoensia pacari stem barks have been
referred in traditional Brazilian and Paraguayan medicines for
cancer treatment, and rare studies concerning their antitumor
activity have been reported, it prompted us to investigate the
behavior of some leukemic cell lines and others representatives of
human cancers when exposed to scaled concentrations of their
extract.
The experimental results of this study clearly showed that the
stem barks of Lafoensia pacari, independently of its preparation
way (as a methanol extract, as a decoction or a macerate), have the
same components’ proﬁle, and exhibit signiﬁcant inhibitory
in vitro effects against the growth and proliferation of several
leukemic and tumor cell lines by triggering cell cycle arrest that
leads to apoptogenic events. They also induced morphological
changes characteristic of apoptosis, which were conﬁrmed by their
high incorporation of annexin V. More interestingly, these effects
were directly related to the concentration used.
Cell cycle arrest and induction of apoptosis are linked events in
which numerous signaling molecules and regulatory proteins are
Fig. 6. Effects of Lafoensia pacari extract on human cell lines. (A) Exponentially growing HRT-18, SH-SY5Y, HeLa cells as well as mononuclear cells (MNC/B) from peripheral
blood exposed to the indicated concentrations of Lafoensia pacari stem barks extract for 24 h were labelled with annexin V and 7-AAD and subject to ﬂow cytometric
analyses to identify subpopulations undergoing early (lower right quadrant/eAp), late (upper right quadrant/lAp) apoptosis or necrosis (upper left quadrant/N). A fraction of
peripheral MNC were pre-treated with phytohemagglutin for 120 h (PHA-MNC) before exposure to extract. (C) Each bar represents the percentage of cells detected in each
quadrant of a representative experiment. nPo0.05; nnPo0.01; nnnPo0.001, all compared to untreated population; #Po0.01 when compared to 10 mg/mL.
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involved in a highly regulated process that occurs as part of
differentiation, proliferation, and growth of normal and malig-
nant cells.
Many medicinal plants possess signiﬁcant anticancer activity,
in which this beneﬁcial health effect may be attributed to one or
more of their constituents. As such, these molecules may interact
with cellular mechanisms, including interference with membrane
and receptors, modulation of signaling cascades, interaction with
enzymes involved in tumor promotion/progression, interaction
with oncogenes and oncoproteins, or direct or indirect interactions
with nucleic acids and nucleoproteins.
Although we did not explore these events at a mechanistical
level and further investigations to identify whether one or more
molecules are responsible for the Lafoensia pacari stem barks
effects are under way, no data concerning to its anticancer
potential as reported in this study are available in the literature.
Therefore, the overall results herein presented are relevant as they
provide the ﬁrst scientiﬁc evidence to support the traditional
anticancer applications of Lafoensia pacari, conﬁrming the indi-
genous wisdom. Moreover, they place this plant as a source of
compounds with the potential to be further exploited for the
discovery and development of new anticancer drugs.
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